Cyclic peptides

ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity

Retrieved on: 
Monday, July 19, 2021
Peptides, Infectious diseases, Health care, Bacterial diseases, Antibiotics, Healthcare-associated infections, Cyclic peptides, Depsipeptides, Daptomycin, Methicillin-resistant Staphylococcus aureus, Vancomycin

The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.

Key Points: 
  • The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.
  • Of note, the addition of CF-296 to both daptomycin or vancomycin resulted in significantly enhanced antibacterial activity in the model, relative to the activity of these standard-of-care antibiotics alone.
  • ContraFect continues to evaluate CF-296 in further preclinical studies and the potential for future clinical development.
  • CF-296 was developed by ContraFect and the Company is actively pursuing global rights to this investigational development candidate.

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

Retrieved on: 
Thursday, May 27, 2021
Organ systems, Medical specialties, Neuroendocrinology, Cyclic peptides, Branches of biology, Octreotide, Opioids, Lanreotide, Somatostatin, Acromegaly

In the MPOWERED study, 146 patients entered the 6-month run-in phase in which all patients received MYCAPSSA.

Key Points: 
  • In the MPOWERED study, 146 patients entered the 6-month run-in phase in which all patients received MYCAPSSA.
  • Ninety-two patients who were responders to MYCAPSSA at end of run-in were then randomized into the 9-month randomized controlled treatment (RCT) phase to receive MYCAPSSA or iSSAs.
  • This non-inferiority clinical trial was designed to compare MYCAPSSA to long-acting injectable somatostatin analogs (SSAs) for maintenance of biochemical response in patients with acromegaly.
  • InJune 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Chiasma to Report Fourth Quarter 2020 Results on March 4

Retrieved on: 
Thursday, February 25, 2021
Branches of biology, Cyclic peptides, Biology, Organ systems, Neuroendocrinology, Octreotide, Opioids, Acromegaly, Lanreotide, Chiasma

An archived replay of the webcast will be available on the Companys website approximately two hours after the event.

Key Points: 
  • An archived replay of the webcast will be available on the Companys website approximately two hours after the event.
  • Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections.
  • In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
  • MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

Retrieved on: 
Tuesday, December 22, 2020
Medical specialties, Branches of biology, Gram-negative bacteria, Pseudomonadales, Clinical medicine, Cyclic peptides, Antibiotic-resistant bacteria, Pseudomonas aeruginosa, Murepavadin, Cystic fibrosis, Pseudomonas, Nebulizer

The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.

Key Points: 
  • The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.
  • The safety, tolerability, and pharmacokinetic study is using eFlow Technology nebulizer (PARI Pharma GmbH) to administer murepavadin Inhalation Solution (MIS) in healthy volunteers.
  • Polyphors inhaled murepavadin is currently being developed as a precision antibiotic specifically for the treatment of chronic Pseudomonas aeruginosa infections in people with CF.
  • Based on the data of the inhaled murepavadin preclinical program suggesting significantly higher safety margins (at least 5-10 times) versus the intravenous formulation, Polyphor is initiating a clinical development program in CF.

CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Retrieved on: 
Tuesday, November 24, 2020
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Genetics, Foundation, Clinical trials, Science, Biotechnology, Other Science, Health, Bacteria, Medical specialties, Branches of biology, Gram-negative bacteria, Pseudomonadales, Antibiotic-resistant bacteria, Bacterial diseases, Cyclic peptides, Cystic fibrosis, Pseudomonas aeruginosa, Pseudomonas infection, Murepavadin

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.

Key Points: 
  • Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.
  • An inhaled version could make it easier for someone with a Pseudomonas infection to take the drug from home.
  • In addition, the drug, which targets the outer membrane of bacteria, specifically focuses on Pseudomonas, which might have certain advantages over broad-spectrum antibiotics.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

Chiasma to Participate in Two Investor Conferences in December

Retrieved on: 
Monday, November 23, 2020
Life sciences, Health sciences, Branches of biology, Cyclic peptides, Neuroendocrinology, Octreotide, Opioids, Acromegaly, Lanreotide, Biopharmaceutical, Therapy, Chiasma

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases.

Key Points: 
  • Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases.
  • Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections.
  • On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
  • MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

Chiasma to Report Third Quarter 2020 Results on November 5

Retrieved on: 
Thursday, October 29, 2020
Branches of biology, Cyclic peptides, Biology, Organ systems, Neuroendocrinology, Octreotide, Opioids, Acromegaly, Lanreotide, Chiasma, Injection

An archived replay of webcast will be available on the Companys website approximately two hours after the event.

Key Points: 
  • An archived replay of webcast will be available on the Companys website approximately two hours after the event.
  • Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections.
  • On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
  • MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program

Retrieved on: 
Wednesday, October 14, 2020
Medical specialties, Gram-negative bacteria, Pseudomonadales, Branches of biology, RTT, Microbiology, Cyclic peptides, Channelopathies, Cystic fibrosis, Pseudomonas aeruginosa, Pseudomonas, Murepavadin

OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.

Key Points: 
  • OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.
  • The companys lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
  • Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).
  • CARB-X is investing up to $480 million from 2016-2022 to support innovative antibiotics and other therapeutics, vaccines and other prevention approaches, and rapid diagnostics.

Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly

Retrieved on: 
Monday, August 31, 2020
Organ systems, Medical specialties, Hormones, Neuroendocrinology, Cyclic peptides, Growth disorders, Growth hormones, Octreotide, Opioids, Lanreotide, Acromegaly, Somatostatin

We are executing on our plan to make MYCAPSSA widely available to potentially address the strong preference by patients with acromegaly for an oral, non-medically administered therapy.

Key Points: 
  • We are executing on our plan to make MYCAPSSA widely available to potentially address the strong preference by patients with acromegaly for an oral, non-medically administered therapy.
  • We plan to expand our customer-facing team as our commercial launch progresses and as we see the level of in-person interactions with healthcare providers increase.
  • MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
  • Chiasma estimates that approximately 8,000 adult acromegaly patients are chronically treated with somatostatin analog injections in the United States.

Chiasma to Report Second Quarter 2020 Results on August 10

Retrieved on: 
Monday, August 3, 2020
Branches of biology, Cyclic peptides, Organ systems, Endocrinology, Neuroendocrinology, Octreotide, Opioids, Acromegaly, Lanreotide, Chiasma, Injection

An archived replay of the webcast will be available on the Companys website approximately two hours after the event.

Key Points: 
  • An archived replay of the webcast will be available on the Companys website approximately two hours after the event.
  • Employing its Transient Permeability Enhancer (TPE) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections.
  • On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
  • MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.